Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review

Drug Dev Res. 2022 Feb;83(1):16-54. doi: 10.1002/ddr.21895. Epub 2021 Nov 11.

Abstract

The coronavirus disease-19 (COVID-19) pandemic has become a global threat since its first outbreak at the end of 2019. Several review articles have been published recently, focusing on the aspects of target biology, drug repurposing, and mechanisms of action (MOAs) for potential treatment. This review gathers all small molecules currently in active clinical trials, categorizes them into six sub-classes, and summarizes their clinical progress. The aim is to provide the researchers from both pharmaceutical industries and academic institutes with the handful information and dataset to accelerate their research programs in searching effective small molecule therapy for treatment of COVID-19.

Keywords: COVID-19; anti-viral agent; small molecules.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • COVID-19 Drug Treatment*
  • Clinical Trials as Topic*
  • Cytokine Release Syndrome / prevention & control
  • Drug Industry
  • Humans
  • SARS-CoV-2*
  • Virus Internalization / drug effects
  • Virus Replication / drug effects

Substances

  • Antiviral Agents